miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
Claire Corcoran(Trinity College Dublin), Lorraine O’Driscoll(Trinity College Dublin)
Cited by 77
Related Papers
Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies
|Obesity Reviews|2014|1.6k
Three-dimensional cell culture: the missing link in drug discovery
|Drug Discovery Today|2012|1.3k
Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles
|OncoImmunology|2017|136
Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2‐positive breast cancer
|International Journal of Cancer|2017|38